What are the Canadian goals of therapy in hyperlipidemia?

Canadian Goals of Therapy in Hyperlipidemia

The Canadian Cardiovascular Society recommends an optimal LDL-C level of ≤2.0 mmol/L (approximately 77 mg/dL) as the primary treatment target for hyperlipidemia, which is more aggressive than U.S. guidelines. 1

Primary Treatment Target

• LDL-C ≤2.0 mmol/L is the primary goal of therapy in Canadian guidelines, representing a more stringent target than the U.S. NCEP ATP III goal of <100 mg/dL for high-risk patients 1
• This target is supported by strong evidence and applies across risk categories, though treatment intensity varies based on individual risk stratification 1

Alternative Treatment Targets

When LDL-C measurement is problematic or when triglycerides are elevated, alternative targets provide equivalent therapeutic guidance:

• Non-HDL-C ≤2.6 mmol/L (approximately 100 mg/dL) is particularly useful when triglycerides are ≥200 mg/dL, as it captures all atherogenic lipoproteins 1
• Apolipoprotein B ≤80 mg/dL represents another evidence-based alternative target that may better reflect particle number in certain populations 1

Secondary Lipid Goals

Beyond the primary LDL-C target, Canadian guidelines recognize additional therapeutic objectives:

• Triglycerides <150 mg/dL as a secondary target 2
• HDL cholesterol >40 mg/dL for men, with consideration of a goal 10 mg/dL higher for women (>50 mg/dL) 2, 1

Risk Stratification Approach

The Canadian approach uses the Framingham Risk Score (FRS) to determine treatment intensity:

• Calculate 10-year total ASCVD risk using FRS 1
• Double the FRS if family history of premature ASCVD exists in first-degree relatives 1
• Categorize patients as low-risk, intermediate-risk (FRS 5-19%), or high-risk to guide treatment decisions 1

For intermediate-risk patients where treatment decisions are uncertain, consider additional testing including lipoprotein(a) levels, high-sensitivity C-reactive protein, coronary calcium scoring, and ankle-brachial index 1

Treatment Implementation Algorithm

Step 1: Initiate lifestyle modifications including dietary changes (saturated fat <7% of energy intake, dietary cholesterol <200 mg/day), weight loss, and increased physical activity 3

Step 2: If LDL-C target is not achieved with lifestyle modifications alone, add statin therapy as first-line pharmacological treatment 1

Step 3: For patients not reaching target on maximally tolerated statin therapy, add ezetimibe 10 mg daily 4

Step 4: For patients with low HDL-C and elevated triglycerides despite adequate LDL-C control, consider adding fibrate therapy (fenofibrate preferred over gemfibrozil when combining with statins to minimize myopathy risk) 1, 3

Step 5: For very high-risk patients not achieving goals with statins and ezetimibe, consider PCSK9 inhibitors 3

Special Populations

Patients with established cardiovascular disease or diabetes: Aggressive LDL-C lowering to the Canadian target of ≤2.0 mmol/L is particularly important, as these patients derive the greatest absolute benefit from intensive lipid lowering 1

Patients with very high triglycerides (>1000 mg/dL): Restrict all types of dietary fat and consider omega-3 fatty acids/fish oils, though monitor LDL-C as these may increase levels 3

Monitoring Strategy

• Assess lipid profile every 3-6 months until target is achieved 3
• Once at target, monitor every 6-12 months 3
• Assess LDL-C as early as 4 weeks after initiating or adjusting therapy 4
• Perform liver enzyme testing as clinically indicated, particularly when combining therapies 4

Critical Pitfalls to Avoid

• Do not use gemfibrozil with statins due to significantly increased myopathy risk; fenofibrate is the preferred fibrate for combination therapy 1, 3
• Administer ezetimibe at least 2 hours before or 4 hours after bile acid sequestrants to avoid binding interactions 4
• Some patients may have normal LDL-C but elevated LDL particle numbers, especially those with metabolic syndrome or diabetes—consider measuring LDL particle number or using non-HDL-C as a surrogate in these populations 3
• When combining fibrates with statins, monitor closely for myopathy symptoms and consider checking creatine kinase if symptoms develop 3, 4